Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LVRNA009 Phase 2 in Chinese adults
NCT05352867Phase 2Completed
- Sponsor
- AIM Vaccine Co., Ltd.
- Start
- Mar 2022
- Primary completion
- Jun 2022
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of LVRNA009 in coronavirus disease 2019 (COVID-19), sponsored by AIM Vaccine Co., Ltd.. Started Mar 2022; status: completed.
02
Drugs
LVRNA009
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05352867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05352867.